Lupin Limited (Lupin) announced the launch of Rufinamide Tablets USP, 200 mg and 400 mg, to market a generic equivalent of Banzel® Tablets, 200 mg and 400 mg, of Eisai Inc. Rufinamide Tablets (RLD Banzel®) had estimated annual sales of USD 138 million in the U.S. (IQVIA MAT October 2022).